365
16. Sitruk-Ware R, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract Res Clin Endocrinol Metab. 2013;27(1):13–24.
17. Sitruk-Ware R, Nath A. Metabolic effects of contraceptive steroids. Rev Endocr Metab Disord.
2011;12(2):63.
18. Krauss RM, Burkman RT Jr. The metabolic impact of oral contraceptives. Am J Obstet
Gynecol. 1992;167(4):1177–84.
19. Patten SB, Williams JV, Lavorato DH, Brown L, McLaren L, Eliasziw M. Major depression,
antidepressant medication and the risk of obesity. Psychother Psychosom. 2009;78(3):182–6.
20. Himmerich H, Minkwitz J, Kirkby KC. Weight gain and metabolic changes during treatment with antipsychotics and antidepressants. Endocr Metab Immune Dis-Drug Targ.
2015;15(4):252–60.
21. Asconapé JJ. Some common issues in the use of antiepileptic drugs. Semin Neurol.
2002;22(1):27–39.
22. Gidal B, Anderson GD, Spencer N, Maly M, Murty J, Pitterle M, et al. Valproate-associated
weight gain: potential relation to energy expenditure and metabolism in patients with epilepsy.
J Epilepsy. 1996;9(4):234–41.
23. Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight
gain: a meta-analysis. PLoS One. 2014;9(4):e94112.
24. Miron IC, Baroană VC, Popescu F, Ionică F. Pharmacological mechanisms underlying the
association of antipsychotics with metabolic disorders. Curr Health Sci J. 2014;40(1):12.
25. Koro C, Meyer J. Atypical antipsychotic therapy and hyperlipidemia: a review. Essent
Psychopharmacol. 2005;6(3):148–57.
26. Michelsen JW, Meyer JM. Cardiovascular effects of antipsychotics. Expert Rev Neurother.
2007;7(7):829–39.
27. Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism.
Diabetes Care. 1991;14(3):203–9.
28. Fonseca VA. Effects of β-blockers on glucose and lipid metabolism. Curr Med Res Opin.
2010;26(3):615–29.
29. de Boer RA, Voors AA, van Veldhuisen DJ. Nebivolol: third-generation β-blockade. Expert
Opin Pharmacother. 2007;8(10):1539–50.
30. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic
effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension:
a randomized controlled trial. JAMA. 2004;292(18):2227–36.
31. Lee P, Kengne A, Greenfield J, Day R, Chalmers J, Ho K. Metabolic sequelae of β-blocker
therapy: weighing in on the obesity epidemic? Int J Obes (Lond). 2011;35(11):1395–403.
32. Katayama S, Attallah AA, Stahl R, Bloch DL, Lee JB. Mechanism of furosemide-induced
natriuresis by direct stimulation of renal prostaglandin E2. Am J Physiol-Renal Physiol.
1984;247(4):F555–F61.
33. Motwani JG. Combining renin-angiotensin-aldosterone system blockade with diuretic therapy
for treatment of hypertension. J Renin Angiotensin Aldosterone Syst. 2002;3(2):72–8.
34. Palmer BF. Metabolic complications associated with use of diuretics. Semin Nephrol.
2011;31(6):542–52.
35. Dronavalli S, Bakris GL. Mechanistic insights into diuretic-induced insulin resistance. Am
Heart Assoc. 2008;52(6):1009–11.
21 Role of Pharmaceuticals as EDCs in Metabolic Disorders
16. Sitruk-Ware R, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract Res Clin Endocrinol Metab. 2013;27(1):13–24.
17. Sitruk-Ware R, Nath A. Metabolic effects of contraceptive steroids. Rev Endocr Metab Disord.
2011;12(2):63.
18. Krauss RM, Burkman RT Jr. The metabolic impact of oral contraceptives. Am J Obstet
Gynecol. 1992;167(4):1177–84.
19. Patten SB, Williams JV, Lavorato DH, Brown L, McLaren L, Eliasziw M. Major depression,
antidepressant medication and the risk of obesity. Psychother Psychosom. 2009;78(3):182–6.
20. Himmerich H, Minkwitz J, Kirkby KC. Weight gain and metabolic changes during treatment with antipsychotics and antidepressants. Endocr Metab Immune Dis-Drug Targ.
2015;15(4):252–60.
21. Asconapé JJ. Some common issues in the use of antiepileptic drugs. Semin Neurol.
2002;22(1):27–39.
22. Gidal B, Anderson GD, Spencer N, Maly M, Murty J, Pitterle M, et al. Valproate-associated
weight gain: potential relation to energy expenditure and metabolism in patients with epilepsy.
J Epilepsy. 1996;9(4):234–41.
23. Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight
gain: a meta-analysis. PLoS One. 2014;9(4):e94112.
24. Miron IC, Baroană VC, Popescu F, Ionică F. Pharmacological mechanisms underlying the
association of antipsychotics with metabolic disorders. Curr Health Sci J. 2014;40(1):12.
25. Koro C, Meyer J. Atypical antipsychotic therapy and hyperlipidemia: a review. Essent
Psychopharmacol. 2005;6(3):148–57.
26. Michelsen JW, Meyer JM. Cardiovascular effects of antipsychotics. Expert Rev Neurother.
2007;7(7):829–39.
27. Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism.
Diabetes Care. 1991;14(3):203–9.
28. Fonseca VA. Effects of β-blockers on glucose and lipid metabolism. Curr Med Res Opin.
2010;26(3):615–29.
29. de Boer RA, Voors AA, van Veldhuisen DJ. Nebivolol: third-generation β-blockade. Expert
Opin Pharmacother. 2007;8(10):1539–50.
30. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic
effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension:
a randomized controlled trial. JAMA. 2004;292(18):2227–36.
31. Lee P, Kengne A, Greenfield J, Day R, Chalmers J, Ho K. Metabolic sequelae of β-blocker
therapy: weighing in on the obesity epidemic? Int J Obes (Lond). 2011;35(11):1395–403.
32. Katayama S, Attallah AA, Stahl R, Bloch DL, Lee JB. Mechanism of furosemide-induced
natriuresis by direct stimulation of renal prostaglandin E2. Am J Physiol-Renal Physiol.
1984;247(4):F555–F61.
33. Motwani JG. Combining renin-angiotensin-aldosterone system blockade with diuretic therapy
for treatment of hypertension. J Renin Angiotensin Aldosterone Syst. 2002;3(2):72–8.
34. Palmer BF. Metabolic complications associated with use of diuretics. Semin Nephrol.
2011;31(6):542–52.
35. Dronavalli S, Bakris GL. Mechanistic insights into diuretic-induced insulin resistance. Am
Heart Assoc. 2008;52(6):1009–11.
21 Role of Pharmaceuticals as EDCs in Metabolic Disorders